Evidence map›Paper›PMID 30630495›Full record

ReviewArthritis research & therapy2019

Common mechanisms and holistic care in atherosclerosis and osteoporosis.

Zoltán Szekanecz, Hennie G Raterman, Zsófia Pethő, Willem F Lems

Open access · goldAbstract readReview
In one paragraph

Review in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Osteoporosis and the long-term risk of peripheral artery disease: a population-based longitudinal follow-up study in Taiwan.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zoltán SzekaneczDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei street 98, Debrecen, 4032, Hungary. szekanecz.zoltan@med.unideb.hu.
Hennie G RatermanDepartment of Rheumatology, Northwest Clinics, Wilhelminalaan 12, Alkmaar, JD, 1815, The Netherlands.
Zsófia PethőDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei street 98, Debrecen, 4032, Hungary.
Willem F LemsAmsterdam Rheumatology and Immunology Centre, Location VU University Medical Centre, Amsterdam 1007 MB, Amsterdam, 1104 LP, The Netherlands.
University of Debrecen · HU

Funding

European Union GINOP-2.3.2-15-2016-00015European Union GINOP-2.3.2-15-2016-00050European Union TAMOP-4.2.4.A/2-11/1-2012-0001
6 · The paper itself

Abstract

Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the aging population and even more in patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, spondyloarthropathies, and systemic lupus erythematosus. In this review, we discuss how the epidemiology and pathogenesis of CV events and OP are overlapping. Smoking, diabetes mellitus, physical inactivity as conventional risk factors as well as systemic inflammation are among the modifiable risk factors for both CV events and bone loss. In rheumatic patients, systemic "high-grade" inflammation may be the primary driver of accelerated atherogenesis and bone resorption. In the general population, in which some individuals might have low-grade systemic inflammation, a holistic approach to drug treatment and lifestyle modifications may have beneficial effects on the bone as well as the vasculature. In rheumatic patients with accelerated inflammatory atherosclerosis and bone loss, the rapid and effective suppression of inflammation in a treat-to-target regime, aiming at clinical remission, is necessary to effectively control comorbidities.

Indexed as

Holistic HealthArthritis, RheumatoidAtherosclerosisBone ResorptionHumansInflammation MediatorsOsteoporosisInflammation MediatorsAtherosclerosisBone lossDXAInflammationOsteoporosisRheumatoid arthritisRisk factors

Identifiers

PMID30630495
PMCPMC6329187
OpenAlexW2912656122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.